文献速递炎症性肠病

联合监测钙卫蛋白与英夫利西单抗可识别克罗恩病黏膜愈合患者

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-05-22

该研究为TAILORIX试验的事后分析(n=122),分析英夫利西单抗诱导和维持治疗期间生物标志物及血清浓度与内镜结局的关系。第2周英夫利西单抗谷浓度>23.1 mg/L、第6周>10.0 mg/L与第12周内镜缓解相关;维持治疗期剂量升级后谷浓度>10.6 mg/L与第54周无溃疡相关。粪便钙卫蛋白持续升高与缺乏内镜应答和缓解相关。

要点

  • 第2周英夫利西单抗谷浓度>23.1 mg/L与第12周内镜缓解相关,阳性预测值72%。
  • 维持治疗期剂量升级后谷浓度>10.6 mg/L与第54周无溃疡相关,阴性预测值92%。
  • 治疗期间粪便钙卫蛋白低水平与内镜应答和缓解相关(P < .05)。

核心结论

  • 在TAILORIX试验的事后分析中,维持治疗期间联合粪便钙卫蛋白浓度与英夫利西单抗谷浓度可指导剂量调整并提高内镜应答和缓解的机会。

研究设计与样本

  • TAILORIX试验(研究英夫利西单抗剂量升级对活动性克罗恩病症状的影响)的事后分析,纳入122例克罗恩病患者,其中116例有内镜结局数据。

主要发现

  • 第2周英夫利西单抗谷浓度>23.1 mg/L和第6周>10.0 mg/L与第12周内镜缓解相关,阳性预测值分别为72%和76%,阴性预测值分别为65%和59%。
  • 维持治疗期间仅在剂量升级后发现暴露-反应关系证据,谷浓度>10.6 mg/L与第54周无溃疡相关,阳性预测值49%,阴性预测值92%。
  • 治疗期间粪便钙卫蛋白低浓度与内镜应答和缓解相关(P < .05)。
  • 剂量升级提高了英夫利西单抗谷浓度;尽管剂量升级,粪便钙卫蛋白浓度持续升高与缺乏内镜应答和缓解相关。
  • 通过耐药物检测法检出英夫利西单抗抗体的患者退出研究的比例显著高于无抗体患者(P < .0001)。

关键数值与推荐

  • 内镜应答定义为克罗恩病内镜严重程度指数较基线下降≥50%。
  • 内镜缓解定义为克罗恩病内镜严重程度指数<3。
  • 主要终点为第12周和第54周的内镜应答、内镜缓解和无溃疡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In the TAILORIX trial, no benefit could be shown by infliximab dose escalation based on pharmacokinetic (infliximab serum concentrations) and pharmacodynamic (biomarkers and symptoms) monitoring compared with dose escalation based on symptoms alone in patients with Crohn's disease (CD). We investigated whether integration of pharmacokinetic and pharmacodynamic monitoring can be used to evaluate responses to infliximab induction and maintenance therapy, based on findings from endoscopy. METHODS: We performed a post hoc analysis of patients with CD included in a trial to test the effects of infliximab dose escalation, based on biomarkers and serum concentrations of infliximab, on symptoms (the Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease trial; n = 122). We analyzed data from this study to determine whether concentrations of biomarkers and serum concentrations of infliximab were associated with endoscopic outcomes (n = 116). The primary end points were endoscopic response (CD endoscopic index of severity decrease ≥50% from baseline), endoscopic remission (CD endoscopic index of severity, <3), and absence of ulcers at weeks 12 and 54 of infliximab treatment. RESULTS: Infliximab trough concentrations greater than 23.1 mg/L at week 2 and greater than 10.0 mg/L at week 6 were associated with endoscopic remission at week 12 (positive predictive values, 72% and 76%; negative predictive values, 65% and 59%, respectively). During maintenance therapy, we found evidence for an exposure-response relationship only after dose escalation; trough concentrations greater than 10.6 mg/L were associated with the absence of ulcers at week 54 (positive predictive value, 49%; negative predictive value, 92%). Low fecal concentrations of calprotectin during therapy were associated with endoscopic response and remission (P < .05). Dose escalations increased trough concentrations of infliximab; persistent increase in fecal concentration of calprotectin, despite dose escalation, was associated with a lack of endoscopic response and remission. A significantly higher proportion of patients with antibodies to infliximab, identified by a drug-tolerant assay, dropped out of the study compared with patients without antibodies (P < .0001). CONCLUSIONS: In a post hoc analysis of data from a trial to test the effects of infliximab dose escalation on symptoms, we found that during maintenance therapy, the combination of fecal concentration of calprotectin and trough concentration of infliximab can guide dose adjustment and increase the chances for endoscopic response and remission. ClinicalTrialsRegister.eu EudraCT no: 2011-003038-14.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dreesen E, Baert F, Laharie D, et al. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. Clin Gastroenterol Hepatol. 2019. PMID: 31128336. doi:10.1016/j.cgh.2019.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。